Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration.

@article{Theysohn2012SelectiveIR,
  title={Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration.},
  author={Jens Matthias Theysohn and Joerg Friedrich Schlaak and Stefan M{\"u}ller and Judith M Ertle and Thomas Wilfried Schlosser and Andreas Bockisch and Thomas Lauenstein},
  journal={Journal of vascular and interventional radiology : JVIR},
  year={2012},
  volume={23 7},
  pages={949-52}
}
Sorafenib, a protein kinase inhibitor, is a systemic drug that has been licensed for the treatment of hepatocellular carcinoma (HCC). This retrospective study assessed whether the administration of sorafenib can result in a reduction of the hepatopulmonary shunt (HPS) before selective internal radiation therapy (SIRT). After exclusion from SIRT because of high HPS, computed tomography scan indicated a shunt reduction in seven patients with HCC receiving sorafenib. Repeated measurements revealed… CONTINUE READING